Public Policy

At Celgene, we believe it is essential to work with public policymakers to help ensure that the policy environment is supportive of patient access to the medications they need and enhances the promise of medical innovation. Our public policy advocacy reflects our commitment to improving the lives of patients and advancing the course of human health through innovation and bold pursuits of science.
Learn more

2019 Value and Innovation Report

This report is intended for U.S. government officials, other healthcare policy makers and healthcare policy opinion leaders.

The Value and Innovation Report examines the different ways in which Celgene’s pursuit of innovation creates value for patients, the health system, the economy and society, and future innovation.

Supply Chain

We expect our suppliers to deliver sustainable solutions while operating at high ethical standards and adhering to fair business practices. These suppliers are part of regional, national and international supply chains that are involved in the manufacturing process for Celgene therapies.
Learn more

Direct-to-Consumer Advertising

Direct-to-consumer (DTC) advertising of prescription medicines can benefit the public health by increasing awareness about diseases, educating patients about treatment options, and motivating patients to contact their physicians to engage in a dialogue about health concerns. DTC advertising can also increase the likelihood that patients will receive appropriate care for conditions that are frequently under-diagnosed and under-treated. Celgene is committed to ensuring that our DTC advertising adheres to applicable FDA regulations and guidance, and the PhRMA Guiding Principles on Direct-to-Consumer (DTC) Advertising About Prescription Medicines.